Chronic obstructive pulmonary disease, or COPD, is a long-term lung condition in which the airways become narrowed and damaged, making it progressively harder to move air in and out of the lungs. The airflow limitation that defines the disease is not fully reversible, which separates COPD from conditions like asthma where breathing can return to normal between episodes. Although it sounds like a single illness, COPD is really an umbrella term that covers a spectrum of overlapping problems, from inflamed, mucus-clogged airways to destroyed air sacs deep in the lungs. Roughly one in ten adults over 40 shows signs of it on breathing tests, yet the majority have never been told they have it.
What Happens Inside the Lungs
Healthy airways are elastic and open. When you exhale, the natural springiness of the lung tissue helps push air out efficiently. In COPD, two things go wrong at once: the small airways become narrowed and obstructed, and the delicate walls of the air sacs (alveoli) where oxygen enters the blood get broken down. The narrowing increases the resistance air meets on the way out, while the loss of air-sac walls reduces the lung’s elastic recoil, so it can no longer snap back into shape the way a healthy lung does.1European Respiratory Journal. Management of Chronic Obstructive Pulmonary Disease Both problems trap stale air in the lungs and make each breath less productive. Over years, this trapped-air effect, called hyperinflation, reshapes the chest and makes physical effort feel disproportionately exhausting.
Chronic Bronchitis, Emphysema, and the Spectrum Between Them
Doctors have historically split COPD into two classic subtypes. Chronic bronchitis refers to ongoing inflammation and excess mucus in the airways; the textbook definition is a productive cough present on most days for at least three months in two consecutive years. Emphysema, by contrast, describes the physical destruction of the air sacs themselves. In chronic bronchitis, goblet cells in the airway lining overproduce mucus, which physically blocks small airways, remodels the lining, and changes the surface tension so airways are more likely to collapse.2PubMed Central. Chronic bronchitis and chronic obstructive pulmonary disease In emphysema, the walls between air sacs are destroyed, leaving fewer, larger spaces that are far less efficient at exchanging oxygen and carbon dioxide.
In practice, most people with COPD sit somewhere between these two extremes rather than neatly in one camp or the other.3PubMed Central. Chronic bronchitis and chronic obstructive pulmonary disease A person might have significant emphysema on a CT scan and still cough up mucus every morning. The two-bucket model persists because the treatments differ somewhat, with mucus-clearing strategies and certain anti-inflammatory drugs mattering more when chronic bronchitis predominates, and surgical or bronchoscopic options becoming relevant when emphysema is severe and localized. But it is more useful to think of COPD as a single disease with a dial between the two rather than two unrelated conditions.
How COPD Is Diagnosed
The standard diagnostic test is spirometry, a simple breathing test where you blow as hard and as fast as you can into a device that measures how much air you move and how quickly. The key number is the ratio of the air you can force out in the first second (FEV1) to the total volume you can blow out (FVC). A low FEV1/FVC ratio indicates that air is having trouble leaving the lungs, which is the hallmark of obstructive disease.4PubMed Central. FEV1/FVC Severity Stages for Chronic Obstructive Pulmonary Disease The test is done after inhaling a bronchodilator (a medication that relaxes airway muscles), because if the airflow limitation disappears completely with the drug, the problem is more likely asthma than COPD.
Where clinicians and researchers disagree is on where to draw the line between “normal” and “low.” The most widely used guideline defines a low ratio as anything below 0.70, a simple fixed cutoff. The alternative approach, called the lower limit of normal, adjusts for age, sex, and height. This matters because the fixed cutoff tends to overdiagnose COPD in older adults, whose lungs naturally lose some elastic recoil with age. A Canadian cohort study found that airflow limitation was present in about 17% of adults using the fixed ratio but only about 11% using the lower limit of normal, and the people caught by the fixed ratio alone did not have meaningfully worse outcomes.5The Annals of Family Medicine. Clinical Relevance of Fixed Ratio vs Lower Limit of Normal of FEV1/FVC in COPD: Patient-Reported Outcomes From the CanCOLD Cohort In other words, using only the fixed cutoff may label some healthy older people as having COPD when they do not.6PubMed Central. Distinguishing adult-onset asthma from COPD: a review and a new approach
Beyond spirometry, imaging is starting to play a larger role. Quantitative CT scanning can detect airway wall thickening and early emphysema before spirometry numbers drop low enough to meet the formal definition, offering a window for earlier intervention.7PubMed Central. Early Diagnosis of High-Risk Chronic Obstructive Pulmonary Disease Based on Quantitative High-Resolution Computed Tomography Measurements CT is not a routine screening tool, but it is increasingly used when symptoms and spirometry results do not line up, or when a doctor wants to see whether emphysema or airway disease dominates.
Causes and Risk Factors
Tobacco smoking remains the single biggest driver. Cigarette smoke triggers chronic inflammation in the airways, damages the cells lining the lungs, disrupts the immune response, and promotes oxidative stress that accelerates tissue breakdown.8PubMed Central. The Role of Smoking in the Mechanisms of Development of Chronic Obstructive Pulmonary Disease and Atherosclerosis Animal studies have confirmed a longstanding idea called the protease-antiprotease hypothesis: smoke activates enzymes (proteases) that chew up the structural proteins in lung tissue, while simultaneously disabling the body’s natural enzyme blockers (antiproteases) that would normally keep those enzymes in check.9PubMed. Mechanisms of cigarette smoke-induced COPD: insights from animal models
But smoking is not the whole story. Indoor air pollution from burning wood, animal dung, or crop waste for cooking and heating is a major risk factor in low- and middle-income countries. A meta-analysis found that people exposed to biomass smoke were roughly two and a half times more likely to develop COPD than those not exposed, with the association holding across geographic regions and in both men and women.10PubMed. Risk of COPD from exposure to biomass smoke: a metaanalysis Disentangling indoor air pollution from other aspects of poverty that can harm lung health, such as childhood infections, poor nutrition, and limited healthcare access, remains challenging, but the link is strong enough to warrant public health attention on its own.11PubMed Central. Household air pollution and COPD: cause and effect or confounding by other aspects of poverty?
On the genetic side, the best-understood risk factor is alpha-1 antitrypsin deficiency, a hereditary condition in which the body produces too little of the protein that normally protects lung tissue from those destructive enzymes. People with this deficiency are prone to developing emphysema at a younger age, especially if they also smoke.12PubMed. Small airways disease in patients with alpha-1 antitrypsin deficiency It accounts for a small fraction of COPD overall, but it matters because it shifts the onset of disease earlier in life and because augmentation therapy (replacing the missing protein) is available.13PubMed. Asthma and COPD in alpha-1 antitrypsin deficiency. Evidence for the Dutch hypothesis
A Massively Underdiagnosed Disease
Population studies across the Americas, Europe, Australia, and Asia consistently find that about 10 to 12 percent of adults aged 40 and older have persistent airflow limitation on spirometry, yet only about 20 to 30 percent of those people have received a COPD diagnosis. That means roughly 70 percent of COPD worldwide goes unrecognized.14PubMed. Underdiagnosis and Overdiagnosis of Chronic Obstructive Pulmonary Disease The underdiagnosis problem is especially severe in rural areas of low- and middle-income countries where spirometry is simply unavailable.15European Respiratory Review. Under- and over-diagnosis of COPD: a global perspective
People often dismiss early symptoms, shortness of breath on a hill they used to climb easily or a morning cough that never quite goes away, as normal aging or a “smoker’s cough.” Doctors, in turn, may not order spirometry when a patient does not fit the stereotypical profile (older male, heavy smoking history). Women, never-smokers, and younger adults with early-stage disease are particularly likely to fall through the cracks. At the same time, overdiagnosis is possible, especially in older adults diagnosed using the fixed-ratio cutoff without a post-bronchodilator test. The global variation is staggering, with one review noting under-diagnosis rates ranging from 10 to 95 percent and over-diagnosis rates from 5 to 60 percent across different settings.16European Respiratory Review. Under- and over-diagnosis of COPD: a global perspective
When Asthma and COPD Overlap
Some people clearly have features of both asthma and COPD, a situation that researchers used to call asthma-COPD overlap syndrome. This is not an entirely separate disease but rather a recognition that the boundaries between the two conditions blur in real patients. Traditional teaching says asthma starts young, responds well to bronchodilators, and involves a specific kind of immune response driven by eosinophils, while COPD starts later, responds poorly to bronchodilators, and involves neutrophils. In practice, many patients have elements of both.17PubMed Central. Distinguishing adult-onset asthma from COPD: a review and a new approach
People in the overlap group tend to have worse outcomes. Systematic reviews have found that overlap patients report more breathlessness and wheezing, experience more frequent and more severe exacerbations, and have lower quality of life scores compared to people with either condition alone.18PubMed Central. Clinical characteristics of the asthma-COPD overlap syndrome–a systematic review In one study, about 17 percent of people diagnosed with COPD met criteria for the overlap phenotype, and those patients scored substantially worse on quality-of-life measures and were less physically active.19PubMed. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status Interestingly, overlap patients tend to have less emphysema on imaging but thicker airway walls, suggesting a different balance of airway inflammation versus tissue destruction compared to “pure” COPD.20European Respiratory Journal. The clinical and genetic features of COPD-asthma overlap syndrome
Exacerbations and Why They Matter
An exacerbation is a flare-up: a stretch of days or weeks where symptoms suddenly worsen beyond the normal day-to-day fluctuations. In practical terms, that usually means noticeably worse breathlessness, more coughing, and a change in the amount or color of sputum. These episodes are often triggered by respiratory infections or spikes in air pollution.21PubMed Central. COPD exacerbations: defining their cause and prevention
Exacerbations are not just bad days. Each one is associated with a burst of inflammation in the lungs and throughout the body, and with the development of further hyperinflation.22PubMed Central. COPD exacerbations: defining their cause and prevention Lung function often does not recover fully after a severe exacerbation, so each event can ratchet the disease forward. Frequent exacerbations predict a faster decline in breathing capacity, more hospital admissions, and higher risk of death. Preventing them, through vaccination, appropriate inhalers, and early treatment of respiratory infections, is one of the most important goals in COPD management.
Researchers have pushed for more precision in how exacerbations are defined. A proposed set of criteria suggests using worsening breathlessness measured on a standardized scale, combined with objective markers like a drop in blood oxygen levels, elevated inflammatory blood markers, and the exclusion of other causes like pneumonia or heart failure.23European Respiratory Journal. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement This kind of precision matters for clinical trials more than for everyday care, but it reflects a growing recognition that the vague label of “getting worse” needs sharper edges if researchers are going to test treatments properly.
COPD as a Whole-Body Disease
One of the most important shifts in how COPD is understood over the past two decades is the recognition that it affects far more than the lungs. Chronic inflammation does not stay contained in the airways; inflammatory molecules spill over into the bloodstream and affect distant organs.24European Respiratory Journal. Systemic manifestations and comorbidities of COPD This “spill-over” helps explain why people with COPD face roughly two to three times the risk of heart disease, stroke, osteoporosis, and muscle wasting compared to people of similar age without the disease.25PubMed. Systemic consequences of COPD
Muscle loss, called sarcopenia, is especially common and debilitating. It creates a vicious cycle: weakened muscles make physical activity harder, which leads to further deconditioning, which worsens breathlessness. Studies have found that COPD patients with sarcopenia walk shorter distances, report more breathlessness, and are more likely to have cardiovascular disease.26PubMed Central. Sarcopenia correlates with systemic inflammation in COPD Depression, diabetes, and anemia are also significantly more common among people with COPD than in the general population of the same age.27European Respiratory Journal. Systemic manifestations and comorbidities of COPD Managing COPD well means managing these associated conditions, not just handing someone an inhaler.
Pre-COPD and Early Structural Changes
A newer concept gaining traction is “pre-COPD,” a stage in which lung function is abnormal but the classic spirometric definition of COPD has not yet been met. One version of this is called preserved ratio impaired spirometry, or PRISm, where the overall amount of air a person can blow out is low, but the FEV1/FVC ratio remains above the diagnostic threshold.28PubMed Central. Preserved ratio impaired spirometry: clinical, imaging and artificial intelligence perspective People with PRISm are at elevated risk of progressing to full COPD.29Scientific Reports. Nomogram to predict progression from preserved ratio impaired spirometry to chronic obstructive pulmonary disease
The concept matters because it opens a window for intervention before irreversible damage accumulates. Someone in the PRISm category who still smokes has a clear, actionable reason to quit. Someone with early airway wall thickening visible on a CT scan but normal spirometry numbers can be monitored more closely rather than being told everything is fine. The traditional definition of COPD, built around a single ratio crossing a threshold, is increasingly seen as too binary for what is really a gradual process.
Predicting How COPD Will Progress
Because spirometry alone does not capture the full picture of how sick someone is, clinicians use composite scoring systems that combine several measurements. The most validated of these is the BODE index, which stands for body mass index, obstruction (measured by FEV1), dyspnea (breathlessness), and exercise capacity (measured by a six-minute walk test). Higher BODE scores correlate with a higher risk of death: for each one-point increase on the ten-point scale, the risk of death from any cause rose by about 34 percent, and the risk of death from respiratory causes rose by about 62 percent.30PubMed. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease The index outperformed FEV1 alone at predicting who would die and when.31The Lancet. Validation of the BODE index: a multicohort study
Pulmonary rehabilitation, a structured program of exercise training, breathing techniques, and education, can improve the BODE score, which makes it one of the most effective interventions in COPD beyond medication.32European Respiratory Journal. Pulmonary rehabilitation and the BODE index in COPD The BODE index is a useful reminder that COPD outcomes depend not just on how damaged your lungs are, but on how well your body can compensate: your weight, your fitness, your ability to keep moving.
Current Treatment Strategy
There is no cure for COPD, but treatment can slow progression, ease symptoms, and reduce the frequency of exacerbations. Current guidelines structure drug treatment as a stepwise escalation. The starting point for most patients who need medication is dual bronchodilation, meaning two types of inhaled drugs that relax the muscles around the airways through different mechanisms. If symptoms or exacerbations persist despite that, the next step is typically adding an inhaled corticosteroid, an anti-inflammatory drug, guided by blood eosinophil counts (a biomarker that helps predict who will respond).33PubMed Central. GOLD 2026: Transforming COPD Management with Early Intervention, Multi-dimensional Assessment, and Personalized Care
Beyond inhalers, smoking cessation is the single intervention with the largest effect on slowing lung function decline. Pulmonary rehabilitation, as mentioned, improves exercise tolerance and quality of life. Vaccination against influenza, pneumococcal bacteria, and COVID-19 reduces the risk of infections that trigger exacerbations. For people with severe disease and low blood oxygen levels, supplemental oxygen therapy improves survival. In select cases of severe emphysema, surgical options like lung volume reduction surgery or, in advanced disease, lung transplantation may be considered.
The Global Economic Toll
COPD is not just a clinical problem but a substantial economic one. A macroeconomic modeling study estimated that COPD will cost the world economy roughly four trillion international dollars between 2020 and 2050, with China and the United States bearing the largest burdens.34The Lancet Global Health. Global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020–50: a health-augmented macroeconomic modelling study That figure includes both the direct costs of healthcare and the indirect costs: lost workdays, reduced productivity, early retirement, and the unpaid labor of caregivers. One study found that over a third of COPD patients received daily help from family or friends, averaging more than three and a half hours a day, multiple days a week.35PubMed Central. Economic Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review The burden falls disproportionately on the same low- and middle-income countries where diagnosis rates are lowest and access to treatment most limited.